Macrae Sandy 4

What Happened
Sandy Macrae, President, CEO and Director of Sangamo Therapeutics (SGMO), surrendered a total of 38,928 shares to the company to satisfy mandatory tax withholding tied to RSU vesting. On Feb 24, 2026 she surrendered 5,291 shares at $0.4725/share (reported proceeds $2,500) and on Feb 25, 2026 she surrendered 33,637 shares at $0.47/share (reported proceeds $15,809). These transactions are reported as dispositions for tax withholding purposes and are not open‑market sales.

Key Details

• Transaction dates and prices: Feb 24, 2026 — 5,291 shares at $0.4725; Feb 25, 2026 — 33,637 shares at $0.47.
• Reported proceeds: $2,500 (Feb 24) and $15,809 (Feb 25); total ≈ $18,309.
• Transaction code: F — shares surrendered to the issuer for mandatory tax withholding (not a discretionary sale).
• Source of shares: vested restricted stock units (RSUs). Footnotes indicate these include 9,456 shares from a Feb 24, 2023 RSU grant and portions of a Feb 25, 2025 RSU RSU grant (the Feb 25, 2026 vesting installment included 60,113 shares; remaining portions vest in scheduled quarterly installments), with vesting subject to continuous service and plan terms.
• Shares owned after the transactions: not specified in the filing.
• Filing: Form 4 filed Feb 26, 2026; transactions reported promptly (no late filing flag).

Context
These were tax‑withholding dispositions tied to RSU vesting (common executive administrative transactions). Because the shares were surrendered to cover taxes under the company’s equity plan, these do not represent an open‑market sale or a discretionary trade and should not be interpreted as a new buy/sell signal by the insider.